16th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome-Reference-Cited by-同舟云学术

16th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome

Published:2020-08-20 Issue:12 Volume:29 Page:1594-1600
ISSN:0961-2033
Container-title:Lupus
language:en
Short-container-title:Lupus

Author:

Cervera Ricard¹^ORCID,Rodríguez-Pintó Ignasi²,Legault Kim³^ORCID,Erkan Doruk⁴

Affiliation:

1. Department of Autoimmune Diseases, Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Catalonia, Spain

2. Systemic Autoimmune Diseases Unit, Hospital Mútua de Terrassa, Terrassa, Catalonia, Spain

3. Division of Rheumatology, Department of Medicine, McMaster University, Hamilton, Canada

4. Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medicine, New York, USA

Abstract

The Task Force on Catastrophic Antiphospholipid Syndrome (CAPS) met again on occasion of the 16th International Congress on Antiphospholipid Antibodies (aPL) that was held in Manchester, England, in September 2019. Its aims were to assess the up-to-date knowledge on pathogenesis, clinical and laboratory features, diagnosis and classification, precipitating factors, and treatment of CAPS. This article summarizes the main aspects that were presented during the Task Force meeting at that Congress.

Publisher

SAGE Publications

Subject

Rheumatology

Link

http://journals.sagepub.com/doi/pdf/10.1177/0961203320951260

Reference25 articles.

1. The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: A comprehensive review

2. Pediatric catastrophic antiphospholipid syndrome: Descriptive analysis of 45 patients from the “CAPS Registry”

3. Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of 500 patients from the International CAPS Registry

4. The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients

5. Rituximab use in the catastrophic antiphospholipid syndrome: Descriptive analysis of the CAPS registry patients receiving rituximab

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathogenesis of antiphospholipid antibody syndrome;Dubois' Lupus Erythematosus and Related Syndromes;2025

2. Antiphospholipid syndrome in the era of COVID-19 – Two sides of a coin;Autoimmunity Reviews;2024-09

3. Catastrophic Thrombosis: A Narrative Review;Seminars in Thrombosis and Hemostasis;2024-08-16

4. Catastrophic antiphospholipid syndrome: challenging case and importance of multidisciplinary evaluation and management;Clinical Case Reports;2024-06

5. Antiphospholipid Patients Admitted in the Intensive Care Unit: What Must The Rheumatologist Know?;Current Rheumatology Reports;2024-04-23